Trial Profile
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Comparison Study of CC-10004 in Subjects With Moderate-to-Severe Plaque-Type Psoriasis.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Apr 2020
Price :
$35
*
At a glance
- Drugs Apremilast (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Amgen; Celgene Corporation
- 04 Mar 2008 New trial record.